Literature DB >> 16877590

The case for further treatment studies of uncomplicated genital Chlamydia trachomatis infection.

P Horner1.   

Abstract

Azithromycin 1 g immediately and doxycycline 100 mg twice daily have good antimicrobial activity against Chlamydia trachomatis and treatment studies have demonstrated a >95% microbiological cure at 2-5 weeks, with antimicrobial resistance being rarely reported. Recently an 8% (95%, CI 5% to 11%) failure rate was observed in 289 women, but not in men, who had been sexually inactive after treatment. At high multiplicities of infection (load) in vitro persistence can often be demonstrated to antimicrobials-heterotypic resistance. The subsequently recovered isolates do not possess antimicrobial resistance at low loads. It is known that genital chlamydia load varies in vivo and is probably greater in women than men. In mass treatment trials of trachoma, treatment failure is associated with high chlamydia loads. It is therefore possible that women with high chlamydia loads may be at increased risk of treatment failure. Given the imminent role out of the National Chlamydia Screening Programme and the consequences of persistent chlamydial infection in women this hypothesis urgently merits further investigation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16877590      PMCID: PMC2564728          DOI: 10.1136/sti.2005.019158

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  26 in total

1.  In vitro susceptibility of recent clinical isolates of Chlamydia trachomatis to macrolides and tetracyclines.

Authors:  Z Samra; S Rosenberg; Y Soffer; M Dan
Journal:  Diagn Microbiol Infect Dis       Date:  2001-03       Impact factor: 2.803

Review 2.  Chlamydial persistence: beyond the biphasic paradigm.

Authors:  Richard J Hogan; Sarah A Mathews; Sanghamitra Mukhopadhyay; James T Summersgill; Peter Timms
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

3.  Ciprofloxacin compared with doxycycline for nongonococcal urethritis. Ineffectiveness against Chlamydia trachomatis due to relapsing infection.

Authors:  T M Hooton; M E Rogers; T G Medina; L E Kuwamura; C Ewers; P L Roberts; W E Stamm
Journal:  JAMA       Date:  1990-09-19       Impact factor: 56.272

4.  Evidence for long-term cervical persistence of Chlamydia trachomatis by omp1 genotyping.

Authors:  D Dean; R J Suchland; W E Stamm
Journal:  J Infect Dis       Date:  2000-08-17       Impact factor: 5.226

5.  Activities of rifamycin derivatives against wild-type and rpoB mutants of Chlamydia trachomatis.

Authors:  Minsheng Xia; Robert J Suchland; Joli A Carswell; John Van Duzer; Debra K Buxton; Kara Brown; David M Rothstein; Walter E Stamm
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

6.  Quantitative culture of Chlamydia trachomatis: relationship of inclusion-forming units produced in culture to clinical manifestations and acute inflammation in urogenital disease.

Authors:  W M Geisler; R J Suchland; W L Whittington; W E Stamm
Journal:  J Infect Dis       Date:  2001-09-28       Impact factor: 5.226

7.  Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure.

Authors:  J Somani; V B Bhullar; K A Workowski; C E Farshy; C M Black
Journal:  J Infect Dis       Date:  2000-04-13       Impact factor: 5.226

8.  Effects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro.

Authors:  U Dreses-Werringloer; I Padubrin; H Zeidler; L Köhler
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

9.  Methodologies and cell lines used for antimicrobial susceptibility testing of Chlamydia spp.

Authors:  R J Suchland; W M Geisler; Walter E Stamm
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

10.  Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials.

Authors:  Chuen-Yen Lau; Azhar K Qureshi
Journal:  Sex Transm Dis       Date:  2002-09       Impact factor: 2.830

View more
  26 in total

1.  Chlamydia trachomatis, Mycoplasma genitalium, and Trichomonas vaginalis infections in men with nongonococcal urethritis: predictors and persistence after therapy.

Authors:  Arlene C Seña; Shelly Lensing; Anne Rompalo; Stephanie N Taylor; David H Martin; Laureen M Lopez; Jeannette Y Lee; Jane R Schwebke
Journal:  J Infect Dis       Date:  2012-05-21       Impact factor: 5.226

2.  Differences in 23S ribosomal RNA mutations between wild-type and mutant macrolide-resistant Chlamydia trachomatis isolates.

Authors:  Yong Jiang; Hui Zhu; Li-Na Yang; Yuan-Jun Liu; Shu-Ping Hou; Man-Li Qi; Quan-Zhong Liu
Journal:  Exp Ther Med       Date:  2015-06-24       Impact factor: 2.447

Review 3.  Chlamydia (uncomplicated, genital).

Authors:  Paddy Horner
Journal:  BMJ Clin Evid       Date:  2010-04-22

Review 4.  Chlamydia (uncomplicated, genital).

Authors:  Megan Crofts; Paddy Horner
Journal:  BMJ Clin Evid       Date:  2015-04-16

Review 5.  Chlamydia (uncomplicated, genital).

Authors:  Paddy Horner
Journal:  BMJ Clin Evid       Date:  2008-06-23

6.  Chlamydia trachomatis variant not detected by plasmid based nucleic acid amplification tests: molecular characterisation and failure of single dose azithromycin.

Authors:  Jose Paolo V Magbanua; Beng Tin Goh; Claude-Edouard Michel; Aura Aguirre-Andreasen; Sarah Alexander; Ines Ushiro-Lumb; Catherine Ison; Helen Lee
Journal:  Sex Transm Infect       Date:  2007-06-13       Impact factor: 3.519

7.  Differential susceptibilities to azithromycin treatment of chlamydial infection in the gastrointestinal tract and cervix.

Authors:  Laxmi Yeruva; Stepan Melnyk; Nicole Spencer; Anne Bowlin; Roger G Rank
Journal:  Antimicrob Agents Chemother       Date:  2013-10-07       Impact factor: 5.191

8.  Impact of azithromycin resistance mutations on the virulence and fitness of Chlamydia caviae in guinea pigs.

Authors:  Rachel Binet; Anne K Bowlin; Anthony T Maurelli; Roger G Rank
Journal:  Antimicrob Agents Chemother       Date:  2010-01-11       Impact factor: 5.191

9.  Induction of the Chlamydia muridarum stress/persistence response increases azithromycin treatment failure in a murine model of infection.

Authors:  R Phillips-Campbell; J Kintner; R V Schoborg
Journal:  Antimicrob Agents Chemother       Date:  2014       Impact factor: 5.191

10.  Frequency of development and associated physiological cost of azithromycin resistance in Chlamydia psittaci 6BC and C. trachomatis L2.

Authors:  Rachel Binet; Anthony T Maurelli
Journal:  Antimicrob Agents Chemother       Date:  2007-10-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.